PDCD1 and skin squamous cell carcinoma: The EMPOWER-CSCC-1 phase 2 clinical trial11 showed the efficacy of cemiplimab, an anti-programmed cell death protein 1 (PD-1) monoclonal antibody, against locally advanced cSCC.